Navigation Links
Study identifies 1 of the mechanisms behind breast cancer metastasis
Date:5/13/2010

BOSTON Several years ago, scientists at Beth Israel Deaconess Medical Center (BIDMC) and other laboratories made a paradoxical discovery regarding the Akt molecular pathway, a popular target for cancer drug therapies. They discovered that while one Akt protein Akt1 was actively preventing cancer cells from spreading, another closely related family member Akt2 was actually promoting breast cancer cell migration. And, indeed, subsequent studies in mouse models of breast cancer revealed that blocking the Akt pathway resulted in enhanced metastasis to the lungs.

This left scientists and clinicians faced with a troubling situation: Would the drugs actively being developed to inhibit Akt activity and halt breast cancer survival mechanisms be simultaneously enhancing cancer cells' abilities to metastasize to other organs?

Now, BIDMC scientists Alex Toker, PhD, and Rebecca Chin, PhD, have identified the first direct Akt1 target, a protein called palladin, providing an explanation for how Akt1 can function as a suppressor of breast cancer invasion and metastasis. This new finding, reported in the May 14, 2010 issue of the journal Molecular Cell, reveals another key piece of information as scientists continue their development of targeted cancer therapies, and underscores the importance of dissecting the precise mechanisms by which tumor cells invade and metastasize to distant organs.

"In 2005, after our lab had made the discovery that Akt was acting as something of a double agent, we wanted to delve into the mechanism that was accounting for opposing functions of these proteins during breast cancer progression," explains Toker, an Associate Professor of Pathology at BIDMC and Harvard Medical School (HMS). "We reasoned that identifying the specific molecular mechanisms by which Akt proteins either inhibit or promote cancer invasion and metastasis would be instrumental for developing more efficient targeted breast cancer therapies."

As with many proteins in cancerous cells, Akt actually exists as a "family" of related proteins, consisting of Akt1, Akt2 and Akt3, explains Chin, an Instructor of Pathology at BIDMC and HMS. "In breast cancer, Akt1 and Ak2 are found, and are frequently hyperactivated due to genetic mutations in the pathway. But we now know that the two family members have opposing functions such that Akt1 inhibits, while Akt2 enhances invasion into the local tumor stroma, leading to metastasis."

To identify novel downstream targets of Akt proteins in breast cancer, the scientists used a discovery-based proteomics approach, coupled with analyses of breast cancer cell lines derived from patients with aggressive metastatic disease. This widely used approach led the authors to identify palladin, a protein known to regulate cell motility and named after the Italian Renaissance architect Andrea Palladio and the Palladian style of architecture.

"Palladin's normal function is to inhibit cell migration and keep cells in place," explains Toker. "By organizing the cellular cytoskeleton at the molecular level, palladin maintains the architecture of the cell in a highly organized manner." But, he adds, because Akt1 regulates palladin in an exclusive manner (by blocking cell motility) when palladin is lost, cells become disorganized, leading to a marked increase in cell migration. "It is believed that the end result is enhanced metastasis, a hypothesis that our lab is continuing to investigate using mouse models of disease progression," notes Toker.

Since the mid-1990s, scientists have known that there exist more than 100 targets of Akt proteins. "But among all of these, only a handful have been shown to be specific to either Akt1 or Akt2," adds Toker. "Our discovery really is the first example of this type of specific mechanism in the Akt pathway, and understanding specific targets is of enormous importance for pharmacological purposes."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Study shows costs and benefits of testosterone in birds
2. Study finds rotavirus vaccine greatly reduces hospitalizations for acute gastroenteritis in children
3. Childhood psychological problems create long-term economic losses, study finds
4. HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings
5. Study demonstrates art therapys effectiveness in pediatric asthma
6. Brain Cell Study Explains Eureka Moment
7. Study Challenges Key Autism Theory
8. New study suggests sickle cell disease may affect brain function in adults
9. Once-A-Year Vitamin D Megadose Ups Fracture Risk: Study
10. Genetic Variants Tied to MS, Study Finds
11. UT Southwestern participates in nationwide study offering free lung tumor genetic testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
Breaking Medicine Technology: